Sol-Gel Technologies (SLGL) and Perrigo (PRGO) Contrast Head-to-Head



[ad_1]

Perrigo (NYSE: PRGO) and Sol Gel Technologies (NASDAQ: SLGL) are both medical companies, but what is the top business? We will compare the two companies based on the strength of their dividends, profitability, earnings, badyst recommendations, institutional ownership, risk and valuation.

Dividends

Perrigo pays an annual dividend of $ 0.76 per share and a dividend yield of 1.0%. Sol Gel Technologies does not pay a dividend. Perrigo pays 15.4% of its profits as a dividend. Perrigo has increased his dividend for 15 consecutive years.

Analyst Notes

This is a summary of the recent recommendations regarding Perrigo and Sol Gel Technologies, provided by MarketBeat.com.

Rating Ranking of places Buy Notes Buy Rating Strong Rank
Perrigo 1 8 8 [19659013] 2.41
Sol Gel Technologies 0 0 4 0 3.00

Perrigo currently has a consensus target price of $ 93.38, suggesting an upside potential of 18.96%. Sol Gel Technologies has a consensus target price of $ 19.00, suggesting a upside potential of 192.31%. Given the highest consensus rating of Sol Gel Technologies and its higher upside potential, badysts clearly believe that Sol Gel Technologies is more favorable than Perrigo

Earnings & Valuation

This table compares the gross revenues of Perrigo and Sol Gel Technologies.

Gross income Price / sales ratio Net income Earnings per share Price / earnings ratio
Perrigo $ 4.95 billion 2.20 [19659013] $ 119.60 million $ 4.93 15.92
Sol Gel Technologies $ 170,000.00 723.41 – $ 31.56 million ] ($ 5.02) -1.29

Perrigo has higher revenues and profits than Sol Gel Technologies. Sol Gel Technologies is trading at a price / earnings ratio lower than Perrigo's, which indicates that it is currently the most affordable of the two stocks.

Ownership of Insiders and Institutions

80.1% of Perrigo shares are held by institutional investors. In comparison, 22.3% of Sol Gel Technologies shares are held by institutional investors. 6.9% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large fund managers believe that a company is ready for long-term growth.

Profitability

This table compares the net margins of Perrigo and Sol Gel Technologies on badets

Net Margins Return on Equity Return on Assets
Perrigo 2.59 % 11.93% 6.23%
Sol Gel Technologies N / A N / A N / A

Abstract

Perrigo beats Sol Gel Technologies on 11 of 15 factors compared between the two stocks

About Perrigo

 Perrigo logo Perrigo Company plc, a health care company, manufactures and supplies health products over-the-counter, infant formula, branded products and generic pharmaceuticals The company operates via Consumer Healthcare Americas, Consumer Healthcare International Segments and Pharmaceuticals Prescription. It offers over-the-counter products for coughs, colds, allergies, sinuses, painkillers, smoking, infant formula and foods, animal health, diagnosis, lifestyle, personal care and dermatological, vitamins and antiparasitics. The company also develops, manufactures and markets a portfolio of generic medicines such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, solid dosage forms and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail chains of drugs, supermarkets and mbad merchandise; hospitals; pharmacies; wholesalers; pharmacies and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel and China. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

About Sol Gel Technologies

 Logo of Sol Gel Technologies "title =" Logo of Sol Gel Technologies "clbad =" companylogo "/> Sol-Gel Technologies Ltd., a specialized pharmaceutical company in phase Clinical, focuses on the development and commercialization of topical dermatological products based on its exclusive microencapsulation delivery system in Israel, including TWIN and SIRS-T, which have completed Phase II clinical trials for the treatment of HIV. Acne vulgaris and Phase II clinical trials for the treatment of papulopustular rosacea, as well as for the development of generic dermatological drugs Sol-Gel Technologies Ltd. has collaborated with Perrigo and Douglas Pharmaceutical for the development and commercialization of A generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Isr Receive news and ratings for Perri go Daily </strong> – Enter your email address below to receive a daily concise summary of the latest news and badyst ratings for Perrigo and related companies with MarketBeat.com's free daily newsletter. 19659066] </pre>
</pre>
[ad_2]
<br /><a href=Source link